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Some subunit vaccines composed of herpes simplex virus (HSV) glycoproteins have been shown to protect guinea pigs
against primary and recurrent genital infection by HSV-2. However, these vaccines were ineffective or only marginally
effective in clinical trials. To attempt to define an animal model that would better discriminate the protective capacity of
different vaccine formulations, we have examined the requirements for vaccine-induced protection against HSV-2 infection
and disease in a mouse genital model. Unlike the guinea pig model where inactivated viral vaccines can protect nearly as
well as live viral vaccines, inactivated viral vaccine afforded little protection in this mouse model. Using replication-defective
mutant viruses as a form of live viral vaccine, we found that the extent of protection conferred by live vaccine was
proportional to the amount of replication-defective mutant virus inoculated, over doses from 104 to 106 PFU. Furthermore, the
mouse genital model showed quantitative differences in the degree of protection induced by various viral vaccine constructs.
An HSV-2 replication-defective mutant virus protected better than an HSV-1 replication-defective mutant that expressed
HSV-2 glycoprotein D, which in turn protected better than an HSV-2 replication-defective mutant virus. We conclude that this
mouse genital model can rank different vaccine constructs for their capacity to induce protective immunity. Thus, genital
infection of the mouse with HSV-2 may provide a stringent animal model that can predict the relative capacity of viral
vaccines to stimulate protective immunity against HSV-2. © 2001 Academic Press
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Herpes simplex virus 2 (HSV-2) is the principal etio-
logic agent of genital herpes. This disease causes a
significant amount of morbidity in infected individuals
and in neonates who contract severe, disseminated in-
fections from their actively infected mothers. Fetuses at
risk for contracting HSV are usually delivered by Cesar-
ean section as a means of prevention, adding signifi-
cantly to health care costs. A recent study reported a 30%
increase in the incidence of HSV-2-mediated genital dis-
ease since the late 1970s; thus, at this time approxi-
mately one in five Americans over the age of 12 is
seropositive for HSV-2 (Fleming et al., 1997). Individuals
may be unaware of their infection, often resulting in silent
transmission to susceptible partners and contributing to
the high rate of infection.
Numerous approaches, including the use of glycopro-
tein subunits, inactivated virus, attenuated mutant HSV
strains, DNA, and recombinant viral vectors expressing
HSV antigens, have been utilized for immunization
against HSV infection and disease in animal model sys-
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256tems (reviewed in Bernstein and Stanberry, 1999; Krause
and Straus, 1999; Stanberry et al., 2000). In particular, the
uinea pig genital model of HSV-2 infection has been
egarded as a useful model for human infection because
rimary and recurrent infections have been defined
Stanberry et al., 1982, 1985). Glycoprotein subunit vac-
ines have proven effective for inducing protective im-
unity in guinea pigs against primary and recurrent
enital infection by HSV-2 (Byars et al., 1994; Stanberry et
al., 1987, 1989a, 1989b). Furthermore, in some experi-
ments inactivated viral vaccine induced protection in
guinea pigs that was nearly equivalent to that produced
by live viral vaccine (Da Costa et al., 1997; McLean et al.,
1994). However, the glycoprotein subunit vaccines were
ineffective at inducing protective immunity in clinical
trials involving prophylactic (Corey et al., 1999; Mertz et
al., 1990) or therapeutic immunization (Straus et al.,
997). Furthermore, an attenuated HSV strain that in-
uced protective immunity in mice against intracranial
ic) challenge (Meignier et al., 1988) was not immuno-
enic in human trials (Cadoz et al., 1992). Because of this
eneral experience, concerns have been raised about
he lack of a discerning animal model for testing herpes
accine candidates (Mascola, 1999).
HSV-1 and HSV-2 replication-defective mutant viruses
ave induced protective immunity in animal studies
gainst lethal intraperitoneal challenge with HSV-1
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257HSV-2 MUTANT VIRUSES AS VACCINES IN A MOUSE MODEL OF INFECTION(Nguyen et al., 1992), ocular challenge with HSV-1 (Mor-
rison and Knipe, 1994), inoculation of HSV-1 into murine
ear pinnae (Farrell et al., 1994), and HSV-2 genital chal-
lenge (Boursnell et al., 1997; Da Costa et al., 1997, 1999;
cLean et al., 1994, 1996; Morrison et al., 1998). We have
sed a mouse genital infection model (McDermott et al.,
984) as modified by Parr et al. (1994) to study the effect
f immunization on HSV-2 challenge virus infection. In
his study we asked whether this mouse system could
istinguish live from inactivated replication-defective mu-
ant virus, whether the protection was dose-dependent,
nd whether the system could distinguish different mu-
ant viral strains in terms of protective immunity. We
bserved that this mouse model of immunization and
ubsequent genital infection does permit us to perceive
ifferences in primary infection, disease severity, and
ethality of challenge virus infection after immunization
ith different virus vaccines.
RESULTS
haracterization of the mouse genital model system
In the herpes simplex vaccine field there is a clear
eed for an animal model that that can be used to test
he relative efficacy of different vaccine constructs for
nducing protective immunity. As described above, gly-
oprotein subunit vaccines that protected against pri-
ary and recurrent genital disease in guinea pigs were
ot efficacious in clinical trials. Thus, an animal model in
hich protection is not induced by glycoprotein subunits
r inactivated virus might better predict the human situ-
tion.
We have used a modified version of the mouse genital
nfection model developed by Parr et al. (1994) to dem-
nstrate the ability of HSV-2 replication-defective mutant
trains to induce protective immunity against genital
hallenge with virulent HSV-2 (Da Costa et al., 1999;
orrison et al., 1998). The latter two studies showed that
ubcutaneous and/or intranasal inoculation of the HSV-2
BlacZ mutant virus could induce protective immunity
gainst genital infection. 5BlacZ is an HSV-2 mutant virus
train in which the UL29 coding sequences are partially
replaced with lacZ coding sequences, rendering the vi-
rus replication-defective in normal cells (Da Costa et al.,
1997). To determine whether inactivated virus could also
confer protection in this mouse genital model, we com-
pared the capacities of live and UV-inactivated 5BlacZ
mutant virus to immunize against genital challenge. Fe-
male BALB/c mice were immunized subcutaneously (sc)
with 106 PFU of 5BlacZ virus, an equivalent amount of
V-inactivated 5BlacZ virus, or an equivalent amount of
ontrol preparation. At 21 days postimmunization, the
ice were challenged with 5 LD50 of HSV-2 strain G by
ntravaginal (i.vag.) inoculation. Immunization with
BlacZ almost completely blocked infection by challenge
irus (Fig. 1A), reducing virus shedding from 3 3 104 PFU
co nearly undetectable levels (P 5 0.0053). In contrast,
he same amount of UV-inactivated 5BlacZ reduced viral
hedding by only about 10-fold over time (Fig. 1A; P 5
.3015). Similarly, UV-inactivated vaccine virus provided
nly partial protection against genital disease (Fig. 1B;
. 0.05) and lethality (Fig. 1C; P . 0.05) while live
accine virus completely protected the animals (P 5
.027 to 0.001 on days 5 through 10 for disease; P 5
.0011 for death). Thus, by several parameters, inacti-
ated vaccine provided very limited protective immunity
n this mouse genital model while live vaccine provided
FIG. 1. Comparison of immunization with live versus UV-inactivated
vaccine virus. Groups of six BALB/c mice were immunized sc with 106
PFU of live 5BlacZ or an equivalent amount of UV-inactivated 5BlacZ or
control preparation. Mice were challenged i.vag. with HSV-2 G. (A)
Virus shedding from the genital tract. Values represent the geometric
mean 6 SEM for each group. (B) Genital disease based on a 5-point
scale. Values represent the arithmetic mean 6 SEM for each group. (C)
Survival of immunized animals.omplete protection.
To examine the quantitative nature of the system, we
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258 DA COSTA, MORRISON, AND KNIPEdetermined the magnitude of the protective immunity in
response to different doses of 5BlacZ virus. We immu-
nized mice sc with 104, 105, or 106 PFU of 5BlacZ and then
hallenged the mice i.vag. with 50 LD50 of HSV-2 G virus.
Immunization with 104 PFU of 5BlacZ reduced viral shed-
ing from the genital tract only slightly (Fig. 2A). Immu-
ization with 105 PFU reduced viral shedding by 1000-
old by day 5 postchallenge (Fig. 2B), and immunization
ith 106 PFU reduced viral shedding by more than 1000-
fold by day 4 and completely eliminated viral shedding by
day 5 (Fig. 2C; P 5 0.0172). Therefore, the level of
FIG. 2. Effect of immunization with different viruses and different
doses on challenge virus shedding from the genital tract. Mice were
immunized with (A) 104, (B) 105, or (C) 106 PFU of different viruses and
hen challenged as described under Materials and Methods. The
enital tracts of mice were swabbed daily postchallenge, and virus titer
n swab samples was determined by standard plaque assay. Values
epresent the geometric mean titer of each group 6 SEM.rotective immunity induced by 5BlacZ in this system, as
easured by reduced challenge virus replication in the
tenital tract, was dependent on the dose of vaccine virus
sed for the immunization.
omparison of protective immunity induced by
ifferent forms of replication-defective
utant viral vaccines
We also wished to determine whether the mouse gen-
tal infection system could be used as an assay to de-
ermine the relative efficacy of several replication-defec-
ive mutant viral strains to induce protective immunity
gainst HSV-2 genital infection. We isolated an intertypic
ecombinant ICP27 mutant virus expressing both HSV-1
lycoprotein D (gD-1) and HSV-2 glycoprotein D (gD-2),
l27gD2 (Fig. 3), for comparison with the parental HSV-1
utant dl27lacZ1 (Fig. 3) and the HSV-2 mutant 5BlacZ
Fig. 3).
To confirm that the intertypic recombinant ICP27 mu-
ant virus dl27gD2 expressed both gD-1 and gD-2, we
esolved the proteins in infected-cell lysates by SDS–
AGE, transferred them to nitrocellulose membranes,
nd probed the membranes with anti-gD-1 or anti-gD-2
abbit antibody (Fig. 4). Two species of gD were detected
y the gD-1 antibody (Fig. 4A). A slower migrating spe-
ies was detected in cells infected with the HSV-1 mu-
ant dl27lacZ1 while a faster migrating species was de-
ected in cells infected with HSV-2 5BlacZ and WT HSV-2
Fig. 4A, lanes 4 and 5). Both species were detected in
ells infected with the HSV-1 recombinant dl27gD2, ar-
uing that it expressed both gD-1 and gD-2 (Fig. 4A, lane
). The anti-gD-2 antibody reacted more specifically with
D-2 (Fig. 4B). The HSV-1 mutant dl27lacZ1 showed no
D-specific bands with this antibody (Fig. 4B, lane 1)
hile dl27gD2 expressed protein that reacted with the
nti-gD-2 antibody (Fig. 4B, lane 2), as did 5BlacZ and WT
SV-2. Thus, dl27gD2 expressed both gD-1 and gD-2.
We then compared HSV-1 dl27lacZ1 and HSV-2 5BlacZ
o the intertypic recombinant dl27gD2 for the capacity to
rotect mice from a lethal genital challenge with HSV-2.
ll animals were immunized by sc injection in the rear
lank and subjected to i.vag. challenge 4 weeks later with
FIG. 3. Genomic maps of the replication-defective mutant strains
used in this study. HSV-1 dl27lacZ1 contains a lacZ expression cassette
in place of part of the UL54 coding sequences. HSV-1 dl27gD2 contains
hat gD-2 gene in place of part of the UL54 coding sequences. HSV-2
5BlacZ contains lacZ sequences inserted into the UL29 ORF.
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259HSV-2 MUTANT VIRUSES AS VACCINES IN A MOUSE MODEL OF INFECTION50 LD50 of WT HSV-2, strain G. Animals were examined
aily for signs of clinical disease and survival, and the
mount of virus shed in the genital tract was determined
y titration of vaginal swabs. As exemplified by disease
cores at 7 days postchallenge, the degree of protection
bserved was both dose- and virus-dependent (Table 1).
t the lowest immunizing dose, 104 PFU, immunized
animals fared no better than those that receiving control
cell lysate and all animals succumbed to infection (Fig.
5A). Animals receiving 105 PFU, however, showed fewer
igns of disease than control animals after challenge
Table 1). At this intermediate dose, dl27gD2 protected
omewhat better than dl27lacZ1 from disease and also
rolonged the time of death (dl27gD2, P 5 0.0088; dl27,
5 0.0088; dl27lacZ1, P 5 0.0309) but time to death in
he dl27gD2-immunized group was less than that of the
BlacZ group (Fig. 5B; P 5 0.0078). At the highest dose
f immunizing virus, 106 PFU, the difference between the
evels of protection in animals receiving dl27lacZ1 or
l27gD2 and those receiving 5BlacZ was equally pro-
ounced (Table 1; 5BlacZ, P 5 0.046 compared with
ontrol). Moreover, the only group in which all the ani-
FIG. 4. Western blot analysis of glycoprotein D by recombinant and
ild-type viral strains. Vero cells were infected with the indicated
iruses or mock-infected. At 9 hpi, the infected cells were harvested
nd gD expression was analyzed by Western blots. (A) R45 anti-gD-1
ntibody. (B) M13 anti-gD-2 antibody.
TABLE 1
Disease Severity in Immunized Animals at 7 Days after Challenge
Immunizing virus
Dose of immunizing virus (PFU)
104 105 106
5BlacZ 4.1 6 0.4a 1.4 6 0.9 0.4 6 0.4
dl27gD2 4.2 6 0.4 2.2 6 0.6 0.9 6 0.7
dl27lacZ 4.1 6 0.4 3.0 6 0.5 1.8 6 0.7t
l
a Mean score 6 SEM of disease for groups of mice (N 5 5)
ssessed on a 5-point scale (see Methods and Materials).als survived the challenge infection was that immu-
ized with 106 PFU of 5BlacZ (Fig. 5C; P 5 0.0078),
lthough the dependence of disease severity and sur-
ival on dose of immunizing virus was evident for both
omotypic and intertypic viruses. The levels of virus shed
n the genital tract largely reflected the severity of dis-
ase observed in the 10 groups of animals. At the 104
PFU immunizing dose, none of the immunized groups
showed significant reduction in acute replication over
time compared with control animals (Fig. 3A). At 105 PFU,
difference in level of challenge virus replication be-
ween immunized and control groups emerged begin-
ing 3 days after challenge (Fig. 3B; P , 0.05 for all
FIG. 5. Effect of immunizing virus and dose on survival after i.vag.
challenge. Groups of five BALB/c mice were immunized sc with (A) 104,
(B) 105, or (C) 106 PFU of the indicated virus or an equivalent amount of
ontrol lysate. Four weeks later all mice were challenged i.vag. with 50
D50 of HSV-2 G. Mice were monitored daily for survival. Results are
from the same experiment as described in the legend to Fig. 2 and
Table 1.hree immunization groups on days 4 and 5 postchal-
enge). Once again, the difference between immunized
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260 DA COSTA, MORRISON, AND KNIPEand control groups was magnified at the 106 PFU dose
(Fig. 3C; P , 0.05 for all three immunization groups on
days 2 through 5). Mice immunized with 5BlacZ showed
the greatest overall reduction in titer (P 5 0.0172), and
5BlacZ was the only immunizing virus for which a dose-
dependent reduction in acute replication of challenge
virus was clearly evident. Levels of virus shed by mice
immunized with dl27gD2 or dl27lacZ1 were comparable
at all doses and times postchallenge. Thus, decreased
replication of challenge virus was dependent on both the
vaccine virus strain and its dose.
DISCUSSION
The apparent efficacy of HSV vaccine candidates in
guinea pig genital models and in mouse ic models con-
trasts with their limited efficacy in clinical trials, as re-
viewed in the Introduction. This has raised concern in the
herpes vaccine field that an appropriate animal model for
testing HSV vaccines may not be available (Mascola,
1999). We have shown in the current study that a mouse
genital infection model of HSV-2 infection has some of
the features that one might postulate to be essential
features of a good model, i.e., better efficacy of live viral
vaccine than inactivated vaccine, levels of protection
dependent on dose of vaccine, the ability to detect quan-
titative differences between different vaccine constructs,
and the ability to show improved protection against
HSV-2 infection with HSV-2 vaccine strains compared
with HSV-1 strains. Obviously, the final proof that the
mouse genital system is a good animal model requires
the proof that efficacious vaccines in this system induce
protective immunity in humans.
Mouse genital infection model
The mouse model that we have used is a modification
of that developed by Parr et al. (1994), who utilized
intravaginal infection of Depo-Provera-treated BALB/c
mice with HSV-2 strain 333. Hormone treatment renders
young adult female mice susceptible to HSV-2 infection
by the vaginal route, and we have found that a second
injection of Depo-Provera increases their sensitivity. We
have utilized the HSV-2 G strain, a clinical isolate pas-
saged a limited number of times in human cells (Ejercito
et al., 1968), as our challenge strain in this system. Five
to 50 LD50 doses for the challenge infection are used to
ush the limits of protection and have demonstrated the
apacity of HSV-2 replication-defective mutant viruses to
rotect against lethal HSV-2 genital challenge (Da Costa
t al., 1999; Morrison et al., 1998). Although the hormone
reatment increases the susceptibility of the mice to
SV-2 infection, this may reduce the similarity to the
uman situation.
u
iomparing live versus inactivated vaccine
In the guinea pig model, glycoprotein subunit vaccines
onsisting of gD-2, gB-2, or gB-2 plus gD-2 (Stanberry et
l., 1987, Stanberry et al., 1989a, 1989b) elicit strong
lycoprotein-specific antibody responses and have pro-
ided solid protection against HSV-2 genital challenge.
urthermore, b-propriolactone-inactivated vaccine virus
as shown strong protective efficacy in the guinea pig
odel (Da Costa et al., 1997; McLean et al., 1994). Nev-
ertheless, subunit vaccines have not been efficacious in
clinical trials, leading to the conclusion that strong cell-
mediated immunity must be induced in addition to neu-
tralizing antibodies for protection in humans (Mascola,
1999).
In the mouse genital infection system, we have dem-
onstrated that live viral vaccine induces complete pro-
tection against lethal challenge virus infection while UV-
inactivated virus vaccine provides only partial protection.
Immunization with live 5BlacZ virus gave statistically
significant decreases in viral shedding, disease, and
mortality compared to the control cell lysate, but UV-
inactivated 5BlacZ virus did not induce statistically sig-
nificant changes in any of these three parameters.
Discerning quantitative and qualitative responses
An important feature of any vaccine assay system is
that the level of immunity induced be proportional to the
dose of the vaccine. Over the range of doses tested in
this study, the level of protective immunity generated
against challenge virus shedding, disease, and mortality
was dependent on the dose of vaccine virus. In fact, the
system was exquisitely sensitive to immunizing dose,
with the spectrum between complete protection and uni-
form disease and death covered by a 100-fold range of
virus inocula.
A second important issue in herpes simplex vaccina-
tion is the capacity to distinguish the optimal virus strain
for protection against HSV-2 at its preferential site of
infection. Given that prior infection with HSV-1 in humans
lowers the probability of genital infection with HSV-2 only
two- to threefold (Bryson et al., 1993; Corey et al., 1983;
ertz et al., 1992), whereas previous infection with a
eterologous strain of HSV-2 considerably lowers the
robability of reinfection (Lakeman et al., 1986; Schmidt
t al., 1984), it seems likely that homotypic immunization
trategies would be most successful in protecting the
enital tract. Previous studies in guinea pigs have shown
hat HSV-1 vaccines can provide a high level of protec-
ion against HSV-2 genital infection (McLean et al., 1994).
ur study clearly indicates a difference between HSV-2
5BlacZ) and HSV-1 (dl127lacZ1) vaccine strains that can-
ot be overcome by provision of gD-2 in the HSV-1
enetic background (dl27gD2). That this system can be
sed to rank different viral vaccines for their efficacy is
ts most important feature.
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261HSV-2 MUTANT VIRUSES AS VACCINES IN A MOUSE MODEL OF INFECTIONClinical trials utilizing gD-2 (Straus et al., 1994) or gD-2
plus gB-2 (Corey et al., 1999; Straus et al., 1994) have
hown that the immunity induced by these glycoproteins
oes not provide adequate protection against HSV-2
nfection. Our results indicate that HSV-2 gD in the con-
ext of a live HSV-1 vaccine also is not sufficient to
rotect against HSV-2 genital infection and disease, al-
hough protection is superior to heterotypic HSV-1 immu-
ization. The strongest protection is obtained with an
SV-2 replication-defective mutant. It is not clear how
any other than HSV-2 gene products gD-2 are needed
o provide the breadth of immunogen necessary for pro-
ective immunity, or which gene products are most im-
ortant immunologically, but our results clearly indicate
hat multiple gene products will be necessary.
The currently available information indicates that ef-
ective immunization against genital HSV-2 infection re-
uires the induction of cellular immunity by way of live
iral vaccination, ideally using a broad range of HSV-2
ntigens. The murine genital infection model system
mployed in this study also indicated an apparent re-
uirement for these features to achieve protective immu-
ity. Further studies are needed to determine whether
he differences between the murine system and guinea
ig system reflect qualitative differences in sensitivity or
re due to the lower doses of virus used in the mouse
odel, the strains of virus used in the different systems,
r differences in the immunology of the two species. In
ny event, our results indicate that this murine system or
efined versions of other animal infection models may be
seful in ranking different genital herpes vaccine candi-
ates for their protective capacity against HSV-2.
MATERIALS AND METHODS
ells and viruses
V27 (Rice and Knipe, 1990) and S2 cells (Gao and
nipe, 1989) were used to propagate ICP27 and ICP8
utant viruses, respectively. The HSV-1 ICP27 mutant
irus, dl27lacZ1 (Rice and Knipe, 1990), and the HSV-2
CP8 mutant virus, 5BlacZ (Da Costa et al., 1997), have
een described previously. HSV-2 strain G (Ejercito et al.,
968) was used as the challenge virus. The construction
f the HSV-1 ICP27 mutant virus, dl27gD2, which ex-
resses both gD-1 and gD-2, is described below. Viruses
sed in immunization studies were prepared as infected-
ell lysates, and all viruses were titered simultaneously
n the same cell line. 5BlacZ was inactivated by expo-
ure to ultraviolet light as described previously (Morrison
nd Knipe, 1994).
onstruction of a double complementing cell line
The construction of cell lines that complement ICP8 or
CP27 mutant viruses has been described previously
Gao and Knipe, 1989; Rice and Knipe, 1990). For theropagation of ICP82/ICP272 double mutant viruses, we
irst constructed an ICP8 and ICP27 double complement-
ng Vero cell line. The procedure was essentially as
escribed previously except that both HSV-1 plasmids
8B-S (Gao and Knipe, 1989) and pBH27 (Rice et al.,
989) were cotransfected along with the plasmid encod-
ng the gene for neomycin resistance. Single colonies
ere picked and tested for their ability to complement
oth ICP8 and ICP27 mutant viruses. One such clone of
ells, named V827, was selected and used for all further
tudies.
lasmids
The HSV-2 strain 186 syn1-1 gD (gD-2) gene was
solated as an XhoI fragment from plasmid pEH43 (Knipe
nd Spang, 1982). Plasmid pPsd27-1 (Rice and Knipe,
990), which lacks the ICP27 ORF, but has flanking HSV
equences, was linearized with BamHI and blunt ended.
unique XhoI site was created at this junction by linker
ddition (59-CCGCTCGAGCGG-39; New England Bio-
abs). The gD-2 gene was cloned into this site and a
ingle plasmid having the gD-2 ORF in the same orien-
ation as that of ICP27 was selected and named pPs27d-
ho-gD2.
onstruction of d27gD2 recombinant virus
An ICP27 mutant virus expressing gD-2 from the UL54
(ICP27) locus was isolated by cotransfecting dl27lacZ1
genomic viral DNA and plasmid pPS27d-Xho-gD2 into
V27 cells using a protocol described previously (Da
Costa et al., 1997). The plasmid was linearized outside
the HSV sequences to facilitate recombination. Progeny
viruses were harvested and replated on V27 cells under
an X-Gal overlay. White plaques representing possible
gD-2 recombinant viruses were selected against a back-
ground of blue parental viruses. Several independently
isolated white plaques were purified at least thrice each
and the presence of the gD-2 gene was confirmed by
Southern hybridization (data not shown). One such virus
was called dl27gD2 (Fig. 1) and used in further experi-
ments.
Immunoblot analysis of gD-1 and gD-2 expression
The capacity of the mutant viruses to express gD was
examined by immunoblot assay. Infected-cell lysates
were subjected to SDS–PAGE, electroblotted onto nitro-
cellulose, and probed for gD-1 or gD-2 expression. Rab-
bit polyclonal sera R-45 (kindly provided by Dr. G. Cohen
and Dr. R. Eisenberg) and anti-gD2T M13 (kindly pro-
vided by Dr. D. C. Johnson) were used as the primary
antibodies to detect gD-1 and gD-2, respectively. Sec-
ondary antibodies and detection reagents were as de-
scribed previously (Da Costa et al., 1997).
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262 DA COSTA, MORRISON, AND KNIPEAnimal studies
Female BALB/c mice, 6 weeks of age, were obtained
from Taconic (Germantown, NY). Mice received food and
water ad libitum and were rested for 1 week before use.
Housing of animals and all protocols and procedures
were approved by institutional guidelines.
Mice were immunized with 106 PFU of replication-
defective virus partially purified from supernatants of
infected cultures, with an equivalent amount of virus that
had been UV-inactivated (Morrison and Knipe, 1994) or
with control supernatants diluted in sterile 0.9% saline. In
a separate experiment, animals were immunized once by
sc injection in the right rear flank near the base of the tail.
Animals received 20 ml of 104, 105, or 106 PFU of viral
ysate or the 106 equivalent amount of control lysate
diluted in sterile 0.9% saline (Sigma, St. Louis, MO). All
animals were challenged at 4 weeks after immunization.
At 1 week and again at 1 day prior to challenge, animals
received 3 mg of medroxyprogesterone (Depo-Provera,
Upjohn) in a volume of 0.1 ml delivered by sc injection
into the neck ruff. All animals were swabbed with a type
1 Calgiswab (Spectrum) and then challenged with 5 3
104 to 5 3 105 PFU of HSV-2 strain G (approximately 5 to
50 LD50) by the i.vag. route. Levels of virus shed from the
genital epithelium were determined by swabbing the
vaginal vault as previously described (Morrison and
Knipe, 1997). Animals also were examined daily for signs
of HSV disease, which was assessed on a 5-point scale
(Morrison et al., 1998).
Statistics
Acute replication titers were compared on individual
days by Student’s t test and over time postchallenge by
area under the curve. The statistical significance of dif-
ference in proportion surviving was determined by the
Fisher exact test and of difference in survival curves by
the log rank test. Disease scores were compared by the
Kruskall–Wallis nonparametric method.
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